Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors.
Heppner D, Wittlinger F, Ogboo B, Shevchenko E, Damghani T, Pham C, Schaeffner I, Oligny B, Chitnis S, Beyett T, Rasch A, Buckley B, Urul D, Shaurova T, May E, Schaefer E, Eck M, Hershberger P, Poso A, Laufer S. Heppner D, et al. Among authors: shevchenko e. Res Sq [Preprint]. 2023 Sep 13:rs.3.rs-3286949. doi: 10.21203/rs.3.rs-3286949/v1. Res Sq. 2023. PMID: 37790373 Free PMC article. Updated. Preprint.
Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation.
Bayrak A, Mohr F, Kolb K, Szpakowska M, Shevchenko E, Dicenta V, Rohlfing AK, Kudolo M, Pantsar T, Günther M, Kaczor AA, Poso A, Chevigné A, Pillaiyar T, Gawaz M, Laufer SA. Bayrak A, et al. Among authors: shevchenko e. J Med Chem. 2022 Oct 13;65(19):13365-13384. doi: 10.1021/acs.jmedchem.2c01198. Epub 2022 Sep 23. J Med Chem. 2022. PMID: 36150079
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.
Spahn S, Kleinhenz F, Shevchenko E, Stahl A, Rasen Y, Geisler C, Ruhm K, Klaumuenzer M, Kronenberger T, Laufer SA, Sundberg-Malek H, Bui KC, Horger M, Biskup S, Schulze-Osthoff K, Templin M, Malek NP, Poso A, Bitzer M. Spahn S, et al. Among authors: shevchenko e. Nat Commun. 2024 Feb 12;15(1):1287. doi: 10.1038/s41467-024-45247-6. Nat Commun. 2024. PMID: 38346946 Free PMC article.
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors.
Wittlinger F, Ogboo BC, Shevchenko E, Damghani T, Pham CD, Schaeffner IK, Oligny BT, Chitnis SP, Beyett TS, Rasch A, Buckley B, Urul DA, Shaurova T, May EW, Schaefer EM, Eck MJ, Hershberger PA, Poso A, Laufer SA, Heppner DE. Wittlinger F, et al. Among authors: shevchenko e. Commun Chem. 2024 Feb 20;7(1):38. doi: 10.1038/s42004-024-01108-3. Commun Chem. 2024. PMID: 38378740 Free PMC article.
Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors.
Rak M, Menge A, Tesch R, Berger LM, Balourdas DI, Shevchenko E, Krämer A, Elson L, Berger BT, Abdi I, Wahl LM, Poso A, Kaiser A, Hanke T, Kronenberger T, Joerger AC, Müller S, Knapp S. Rak M, et al. Among authors: shevchenko e. J Med Chem. 2024 Mar 14;67(5):3813-3842. doi: 10.1021/acs.jmedchem.3c02217. Epub 2024 Feb 29. J Med Chem. 2024. PMID: 38422480
Shifting the selectivity of pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily.
Rak M, Tesch R, Berger LM, Shevchenko E, Raab M, Tjaden A, Zhubi R, Balourdas DI, Joerger AC, Poso A, Krämer A, Elson L, Lučić A, Kronenberger T, Hanke T, Strebhardt K, Sanhaji M, Knapp S. Rak M, et al. Among authors: shevchenko e. Eur J Med Chem. 2023 Jun 5;254:115347. doi: 10.1016/j.ejmech.2023.115347. Epub 2023 Apr 7. Eur J Med Chem. 2023. PMID: 37094449
198 results